Repligen Corporation $RGEN Stock Sold by Krilogy Financial LLC

Key Points

• Krilogy Financial reduced its Repligen stake by 31.8% in the third quarter, selling 7,033 shares and retaining 15,066 shares valued at approximately $2.9 million.
• Institutional ownership remains high at 97.64%, with several major investors increasing or initiating positions in Repligen.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $173.21; Benchmark upgraded the stock to “Buy” with a $185 target.

Krilogy Financial LLC lowered its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 31.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,066 shares of the biotechnology company's stock after selling 7,033 shares during the quarter. Krilogy Financial LLC's holdings in Repligen were worth $2,896,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. United Capital Financial Advisors LLC bought a new position in shares of Repligen in the 2nd quarter worth about $380,756,000. Wasatch Advisors LP lifted its stake in shares of Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock valued at $216,974,000 after purchasing an additional 346,720 shares during the period. Maverick Capital Ltd. bought a new stake in shares of Repligen during the 1st quarter valued at about $178,946,000. Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 3.8% during the 1st quarter. Conestoga Capital Advisors LLC now owns 1,097,783 shares of the biotechnology company's stock valued at $129,341,000 after purchasing an additional 39,808 shares in the last quarter. Finally, Congress Asset Management Co. boosted its position in shares of Repligen by 0.9% during the 3rd quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company's stock valued at $196,249,000 after purchasing an additional 8,681 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

RGEN has been the subject of several recent analyst reports. Benchmark raised Repligen from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Weiss Ratings raised Repligen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Zacks Research lowered Repligen from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 28th. UBS Group restated a "buy" rating on shares of Repligen in a report on Tuesday, September 29th. Finally, Evercore reaffirmed an "outperform" rating and set a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $173.21.

Repligen Trading Up 1.6%

RGEN opened at $178.20 on Thursday. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $198.87. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The company has a market cap of $10.06 billion, a P/E ratio of 89.05, a price-to-earnings-growth ratio of 3.20 and a beta of 1.08. The company has a fifty day moving average price of $175.13 and a two-hundred day moving average price of $144.78.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company's portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.